Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction

Journal of Interventional Cardiology

Volumn 15, Issue 2, 2002, Pages 131-139

  Vivekananthan, Deepak P ^a   Patel, Vasant B ^a   Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BITISTATIN; ECHISTATIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; KISTRIN; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; STREPTOKINASE; TENECTEPLASE; TIROFIBAN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; EMERGENCY WARD; FIBRINOLYSIS; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HUMAN; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

EID: 0036096723     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2002.tb01045.x     Document Type: Article

References (58)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)
2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
3. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
4. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial
5. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial
6. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
7. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction
8. A randomized trial of late reperfusion therapy for acute myocardial infarction
9. Early thrombolysis in acute myocardial infarction: Limitation of infarct size and improved survival
10. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)
11. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction
12. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
13. Zwolle myocardial infarction study group: Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction
14. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: Importance of microvascular reperfusion on clinical outcome
15. ST-segment resolution and infarct related artery patency and flow after thrombolytic therapy
16. Extent of early ST segment elevation resolution: A strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens: A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial
17. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
18. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
19. Thrombolytic therapy for acute myocardial infarction
20. A comparison of reteplase with alteplase for acute myocardial infarction
21. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double blind randomised trial
22. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
23. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
24. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial
25. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction
26. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
27. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis
28. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
29. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis
30. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model
31. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs
32. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation
33. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
34. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis
35. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis
36. Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles
37. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation
38. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study
39. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial
40. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial
41. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial
42. Abxicimab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 Trial
43. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
44. Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial Infarction
45. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: The Integrilin and Low-Dose Thrombolysis in Acute Myocardial Infarction - INTRO AMI Trial
46. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
47. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
48. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy
49. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
50. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients
51. Effect of age on outcome with primary angioplasty versus thrombolysis
52. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
53. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
54. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
55. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
56. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial
57. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction
58. Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: New therapeutic regimen for acute myocardial infarction